August 2024 - Page 10 of 19

AIDS Interview丨Inhibiting HIV Transcription to Achieve Maximum Disease Remission

By Mourabit Halima 2024.08.16

At the AIDS 2024 conference, Dr. Melanie Ott from the University of California, San Francisco, delivered a special report titled "The Sound of Silence: Tackling HIV Transcription to Achieve Remission," which garnered widespread attention. Following the conference, Infectious Diseases Frontier conducted an in-depth interview with Dr. Ott, where she elaborated on the significance of HIV transcription mechanisms in regulating viral reservoirs, which play a crucial role in the rebound of the virus after treatment interruption. Professor Ott highlighted that a novel strategy involving the use of transcription inhibitors in combination with existing antiretroviral therapy (ART) could potentially suppress transcriptional activity in reservoir cells, thereby delaying viral rebound and reducing immune activation, bringing new hope and breakthroughs to the field of HIV treatment.

Dr. Yingli He: Building a Defense Against Liver Cancer—Antiviral Treatment Strategies for CHB Patients in the Context of Comprehensive Liver Cancer

By Mourabit Halima 2024.08.16

Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) presents a significant public health challenge in China, with the majority of HCC patients being diagnosed at an advanced stage. Postoperative survival rates for HBV-related HCC patients are often poor. Therefore, the prevention and treatment of HBV-related HCC urgently require comprehensive management. China has achieved remarkable success in primary prevention of hepatitis B. Regular screening and early treatment in high-risk populations are crucial to reducing HCC mortality. Antiviral treatment is an important measure for secondary and tertiary prevention of HBV-related HCC. At the 2024 World Hepatitis Day and the Elimination of Hepatitis Harm Action Conference, Dr. Yingli He from the First Affiliated Hospital of Xi'an Jiaotong University shared insights into antiviral treatment strategies for chronic hepatitis B (CHB) patients from the perspective of comprehensive liver cancer management.

How Should Chinese Women Approach Breast Cancer Screening?

By Mourabit Halima 2024.08.16

Breast cancer has now become the most common malignant tumor worldwide and is one of the most prevalent cancers among Chinese women, posing a serious threat to their physical and mental health. While significant progress has been made in the treatment and drug development for breast cancer, providing more targeted treatment options for different types of patients and improving survival rates and quality of life, our ultimate goal is to reduce the incidence of breast cancer through screening and prevention. Early detection is crucial for improving treatment outcomes and extending survival times. This article discusses breast cancer screening and how high-risk groups can reduce their risk of developing breast cancer.

In-Depth Analysis | Dr. Yuhua Song & Dr. Jing Yao: Treatment Options for HR+/HER2- Breast Cancer Patients After CDK4/6i Progression

By Mourabit Halima 2024.08.16

After CDK4/6i treatment failure in HR+/HER2- breast cancer patients, do you lean more towards a PI3K inhibitor or an AKT inhibitor? At the Northern Salon of the 2024 Summer Breast Cancer Forum, during the "In-Depth Analysis" segment, Dr. Yuhua Song from The Affiliated Hospital of Qingdao University and Dr. Jing Yao from Union Hospital Affiliated with Huazhong University of Science and Technology each presented their views. Professor Song expressed a preference for PI3K inhibitors, while Professor Yao favored AKT inhibitors. Following the session, Cancer Outlook invited both experts to elaborate on their perspectives.

In-Depth Analysis | Dr. Xuening Ji & Dr. Chunfang Hao: Treatment Options After TKI Therapy Failure in HER2-Positive Breast Cancer

By Mourabit Halima 2024.08.16

After the failure of TKI therapy in HER2-positive breast cancer, would you prefer an "ADC" or "HP+" regimen? At the Northern Salon of the 2024 Summer Breast Cancer Forum, during the "In-Depth Analysis" segment, Dr. Xuening Ji from Affiliated Zhongshan Hospital of Dalian University and Dr. Chunfang Hao from Tianjin Cancer Hospital shared their perspectives. Professor Ji advocated for the ADC approach, while Professor Hao supported the "HP+" regimen. Following the session Oncology frontier invited both experts to elaborate on their viewpoints.

Dr. Jidong Jia: Progress and Challenges in the Prevention and Treatment of Hepatitis B in China

By Mourabit Halima 2024.08.15

China has historically been a high-prevalence area for Hepatitis B virus (HBV) infection, with a hepatitis B surface antigen (HBsAg) prevalence rate of 9.7% in 1992. Comprehensive strategies, including the hepatitis B vaccine program for newborns (HepB), with a strong emphasis on timely administration of the birth dose and completion of the three-dose schedule, have significantly reduced mother-to-child transmission and early childhood HBV infections. With the significant reduction in the cost of antiviral drugs, treatment accessibility and affordability have greatly improved. From July 20 to 21, the "2024 World Hepatitis Day Campaign and Hepatitis Elimination Action Conference" was held in Beijing. Dr. Jidong Jia from Beijing Friendship Hospital ,Capital Medical University delivered a keynote speech titled "Progress and Challenges in the Prevention and Treatment of Hepatitis B in China," where he systematically explained the progress made, the challenges faced, and the urgent actions needed in the prevention and treatment of hepatitis B in China.

Expert Commentary | Dr. Lin Zhang: Immune Activation as the Foundation for Sustained Efficacy of Yttrium-90 Radioembolization in Liver Cancer

By Mourabit Halima 2024.08.15

Yttrium-90 (Y90) resin microsphere selective internal radiotherapy (Y90-RE) is a minimally invasive local treatment method that can effectively control tumor progression in hepatocellular carcinoma (HCC) patients who are ineligible for resection or ablation, with compensated liver function and good overall condition. With the advancement of precision medicine, the clinical understanding of immune activation by Y90-RE has deepened, revealing the potential of pre-Y90-RE peripheral blood mononuclear cell (PBMC) immune profiling in predicting patient prognosis. Hepatology Digest invited Dr. Lin Zhang from Beijing Tsinghua Changgung Hospital to interpret a study published in Gut (IF=23), which explores the immune activation mechanisms of Y90-RE.

SIFIC Insights: “The Essential Growth Path for Infection Control Professionals” & “Supporting the Future of China’s Infection Control Field”

By Mourabit Halima 2024.08.15

The 20th Shanghai International Forum for Infection Control (SIFIC), in conjunction with the 8th Oriental Forum on Challenging Infectious Diseases (OFCID) and the Academic Corference of Global Chinese Association of Clinical Microbiology & Infectious Diseases (SIFIC 2024 "National Infection Control and Challenging Infectious Diseases" Combined Conference), was grandly inaugurated in Shanghai. "Xiaoshi," a reporter from Infection Medical Line, interviewed some of the participants at the SIFIC event, sharing the growth journey and bright future of SIFIC.

Precision Diagnosis and Control: SIFIC’s milestone conference for 20 years opens, drawing a new blueprint for infection control

By Mourabit Halima 2024.08.15

On July 26, 2024, the highly anticipated 20th Shanghai International Forum for Infection Control (SIFIC), in conjunction with the 8th Oriental Forum on Complex Infectious Diseases (OFCID) and the Annual Meeting of the Global Chinese Society of Clinical Microbiology and Infectious Diseases, was grandly inaugurated at the Shanghai International Conference Center. Themed "Precision Diagnosis, Precision Control," this year's conference aims to enhance the scientific and precise approach to infection prevention and control in China. Marking SIFIC's 20th anniversary, the conference not only reflected on past achievements but also looked forward to the boundless possibilities in the field of infection control, inspiring every participant to move forward together in writing a new chapter for infection prevention and control.

Emerging Perspectives: July Literature Digest (Part 2)

By Mourabit Halima 2024.08.15

In today’s information overload era, how can one stay updated on the latest advancements in the field? Here, we curate the most recent literature each month, focusing on hot topics and offering a comprehensive analysis of the latest developments in hematologic diseases. Join us as we track the latest trends, gain insights into scientific research, and explore the limitless possibilities in the world of hematology. Stay tuned—don’t miss our monthly updates!